

PRESS RELEASE

STRATEC completes acquisition of Diatron

Birkenfeld, April 1, 2016

STRATEC Biomedical AG, Birkenfeld, Deutschland (Frankfurt: SBS; Prime Standard, TecDAX) today announces the successful completion of the acquisition of Diatron MI PLC (Diatron). On March 23, 2016, STRATEC announced that it entered into an agreement with the global private equity firm The Riverside Company governing the full acquisition of Diatron, its US affiliate company and the superordinate holding structure.

With the acquisition of Diatron, STRATEC is extending its range of products and its customer base in the hematology segment. Diatron's OEM portfolio chiefly comprises analyzer systems, system components, consumables and tests in the lower throughput segment for hematology applications.

About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:

STRATEC Biomedical AG

André Loy, Corporate Communications

Gewerbestr. 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916-190

Fax: +49 7082 7916-999

ir@stratec.com

www.stratec.com